KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma
Investigators attempted to map the cell-to-cell communications in Ewing sarcoma (ES) and use this map to identify potential new therapies. They used a technique called single-cell RNA sequencing (scRNA-seq) data analysis to determine how the cells within the ES tumor microenvironment (TMA) communicated with each other. The analysis indicated that multi-kinase anti-angiogenic inhibitors may be effective against ES. The investigators then tested a novel multi-kinase inhibitor, KC1036, in ES cancer cell lines and mouse models of ES. The first mouse model uses an ES cell line implanted in a mouse and the second uses cells from a patient’s tumor implanted into the mouse. In both cases the drug of interest is then used to determine efficacy against the implanted tumors. The results of these series of experiments indicate that KC1046 may be effective against ES. These are early results, and many additional studies are needed, but they indicate that this multi-kinase inhibitor may be a therapeutic option in ES.
Read the full study in Angiogenesis.